IDYA
Price
$14.77
Change
-$0.80 (-5.14%)
Updated
Apr 4, 02:40 PM (EDT)
Capitalization
1.36B
39 days until earnings call
RCUS
Price
$7.01
Change
-$0.16 (-2.23%)
Updated
Apr 4, 02:50 PM (EDT)
Capitalization
758.88M
39 days until earnings call
Ad is loading...

IDYA vs RCUS

Header iconIDYA vs RCUS Comparison
Open Charts IDYA vs RCUSBanner chart's image
IDEAYA Biosciences
Price$14.77
Change-$0.80 (-5.14%)
Volume$100
Capitalization1.36B
Arcus Biosciences
Price$7.01
Change-$0.16 (-2.23%)
Volume$329
Capitalization758.88M
IDYA vs RCUS Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. RCUS commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and RCUS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (IDYA: $15.57 vs. RCUS: $7.17)
Brand notoriety: IDYA and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 154% vs. RCUS: 193%
Market capitalization -- IDYA: $1.36B vs. RCUS: $758.88M
IDYA [@Biotechnology] is valued at $1.36B. RCUS’s [@Biotechnology] market capitalization is $758.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both IDYA and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while RCUS’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • RCUS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -10.67% price change this week, while RCUS (@Biotechnology) price change was -15.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.29%. For the same industry, the average monthly price growth was -17.13%, and the average quarterly price growth was -18.92%.

Reported Earning Dates

IDYA is expected to report earnings on May 13, 2025.

RCUS is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-11.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.36B) has a higher market cap than RCUS($759M). IDYA YTD gains are higher at: -39.416 vs. RCUS (-51.847). RCUS has higher annual earnings (EBITDA): -269M vs. IDYA (-323.14M). RCUS has more cash in the bank: 978M vs. IDYA (676M). IDYA has less debt than RCUS: IDYA (19.2M) vs RCUS (60M). RCUS has higher revenues than IDYA: RCUS (258M) vs IDYA (7M).
IDYARCUSIDYA / RCUS
Capitalization1.36B759M180%
EBITDA-323.14M-269M120%
Gain YTD-39.416-51.84776%
P/E RatioN/AN/A-
Revenue7M258M3%
Total Cash676M978M69%
Total Debt19.2M60M32%
FUNDAMENTALS RATINGS
IDYA vs RCUS: Fundamental Ratings
IDYA
RCUS
OUTLOOK RATING
1..100
5653
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
9194
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (57) in the Pharmaceuticals Major industry is in the same range as IDYA (60) in the null industry. This means that RCUS’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (70) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to RCUS’s over the last 12 months.

IDYA's SMR Rating (95) in the null industry is in the same range as RCUS (97) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to RCUS’s over the last 12 months.

IDYA's Price Growth Rating (91) in the null industry is in the same range as RCUS (94) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that RCUS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYARCUS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 23 days ago
77%
Bullish Trend 30 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ISCIX43.30N/A
N/A
Federated Hermes Intl Small-Mid Co IS
FNIAX39.28N/A
N/A
Fidelity Advisor New Insights A
KDHSX54.96N/A
N/A
DWS CROCI Equity Dividend S
MMUIX22.96N/A
N/A
MFS Utilities I
HSDEX8.84N/A
N/A
Hartford Schroders Diversified EmMktsSDR

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-4.77%
GRI - IDYA
54%
Loosely correlated
-13.77%
KRYS - IDYA
51%
Loosely correlated
-1.59%
IMNM - IDYA
51%
Loosely correlated
-7.00%
RCKT - IDYA
50%
Loosely correlated
-11.75%
XENE - IDYA
49%
Loosely correlated
-2.38%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with APGE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-9.13%
APGE - RCUS
43%
Loosely correlated
-7.51%
ACLX - RCUS
42%
Loosely correlated
-7.12%
ATXS - RCUS
41%
Loosely correlated
-6.70%
IDYA - RCUS
40%
Loosely correlated
-4.77%
ITOS - RCUS
40%
Loosely correlated
-1.21%
More